Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$151.75
+1.0%
$135.24
$91.86
$254.15
$7.38B1.481.02 million shs880,066 shs
Icon Plc stock logo
ICLR
Icon
$146.75
+0.6%
$139.03
$125.10
$347.72
$11.78B1.151.11 million shs1.16 million shs
Incyte Corporation stock logo
INCY
Incyte
$70.81
+4.8%
$64.29
$53.56
$83.95
$13.08B0.672.00 million shs3.03 million shs
IQVIA Holdings Inc. stock logo
IQV
IQVIA
$158.00
-0.4%
$148.98
$134.65
$252.88
$27.46B1.281.65 million shs2.55 million shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
+1.00%+4.48%+9.31%-2.48%-26.63%
Icon Plc stock logo
ICLR
Icon
+0.58%+2.21%+11.70%-18.05%-53.11%
Incyte Corporation stock logo
INCY
Incyte
+4.83%+3.72%+8.36%+16.85%+14.67%
IQVIA Holdings Inc. stock logo
IQV
IQVIA
-0.48%+2.18%+12.40%-10.87%-25.18%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
4.8055 of 5 stars
3.15.00.04.73.02.51.9
Icon Plc stock logo
ICLR
Icon
4.6237 of 5 stars
4.35.00.00.02.13.32.5
Incyte Corporation stock logo
INCY
Incyte
4.5286 of 5 stars
2.14.00.03.13.22.53.1
IQVIA Holdings Inc. stock logo
IQV
IQVIA
4.9108 of 5 stars
4.43.00.04.63.01.72.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
2.18
Hold$171.8513.24% Upside
Icon Plc stock logo
ICLR
Icon
2.60
Moderate Buy$213.0845.20% Upside
Incyte Corporation stock logo
INCY
Incyte
2.22
Hold$74.535.26% Upside
IQVIA Holdings Inc. stock logo
IQV
IQVIA
2.75
Moderate Buy$226.3243.24% Upside

Current Analyst Ratings Breakdown

Latest IQV, ICLR, INCY, and CRL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/23/2025
Incyte Corporation stock logo
INCY
Incyte
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetSector Perform ➝ Sector Perform$67.00
6/16/2025
Incyte Corporation stock logo
INCY
Incyte
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$75.00 ➝ $107.00
6/3/2025
Incyte Corporation stock logo
INCY
Incyte
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
6/3/2025
Incyte Corporation stock logo
INCY
Incyte
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$61.00
5/27/2025
Incyte Corporation stock logo
INCY
Incyte
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$72.00 ➝ $73.00
5/23/2025
IQVIA Holdings Inc. stock logo
IQV
IQVIA
Redburn Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$188.00
5/23/2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$188.00 ➝ $182.00
5/22/2025
IQVIA Holdings Inc. stock logo
IQV
IQVIA
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
5/19/2025
IQVIA Holdings Inc. stock logo
IQV
IQVIA
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$232.00 ➝ $177.00
5/15/2025
Icon Plc stock logo
ICLR
Icon
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$200.00 ➝ $173.00
5/15/2025
IQVIA Holdings Inc. stock logo
IQV
IQVIA
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$210.00 ➝ $190.00
(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$4.05B1.84$21.93 per share6.92$67.80 per share2.24
Icon Plc stock logo
ICLR
Icon
$8.28B1.43$20.16 per share7.28$117.92 per share1.24
Incyte Corporation stock logo
INCY
Incyte
$4.24B3.23$0.58 per share122.02$17.90 per share3.96
IQVIA Holdings Inc. stock logo
IQV
IQVIA
$15.41B1.77$16.53 per share9.56$33.43 per share4.73
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$22.20M-$0.65N/A13.804.63-0.66%15.19%6.93%8/6/2025 (Estimated)
Icon Plc stock logo
ICLR
Icon
$791.47M$9.1815.999.601.539.25%11.46%6.49%7/23/2025 (Estimated)
Incyte Corporation stock logo
INCY
Incyte
$32.62M$0.32221.2910.830.570.48%2.77%1.77%7/29/2025 (Estimated)
IQVIA Holdings Inc. stock logo
IQV
IQVIA
$1.37B$7.3421.5312.951.748.61%29.16%6.96%7/28/2025 (Estimated)

Latest IQV, ICLR, INCY, and CRL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/23/2025Q2 2025
Icon Plc stock logo
ICLR
Icon
$3.18N/AN/AN/A$1.98 billionN/A
5/7/2025Q1 2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$2.06$2.34+$0.28$0.50$942.34 million$984.17 million
5/6/2025Q1 2025
IQVIA Holdings Inc. stock logo
IQV
IQVIA
$2.63$2.70+$0.07$1.40$3.77 billion$3.83 billion
4/30/2025Q1 2025
Icon Plc stock logo
ICLR
Icon
$3.17$3.19+$0.02$1.90$2.03 billion$2.00 billion
4/29/2025Q1 2025
Incyte Corporation stock logo
INCY
Incyte
$1.01$1.16+$0.15$0.80$996.17 million$1.05 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
N/AN/AN/AN/AN/A
Icon Plc stock logo
ICLR
Icon
N/AN/AN/AN/AN/A
Incyte Corporation stock logo
INCY
Incyte
N/AN/AN/AN/AN/A
IQVIA Holdings Inc. stock logo
IQV
IQVIA
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
0.78
1.43
1.16
Icon Plc stock logo
ICLR
Icon
0.36
1.27
1.27
Incyte Corporation stock logo
INCY
Incyte
0.01
2.04
2.00
IQVIA Holdings Inc. stock logo
IQV
IQVIA
2.19
0.82
0.82

Institutional Ownership

CompanyInstitutional Ownership
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
98.91%
Icon Plc stock logo
ICLR
Icon
95.61%
Incyte Corporation stock logo
INCY
Incyte
96.97%
IQVIA Holdings Inc. stock logo
IQV
IQVIA
89.62%

Insider Ownership

CompanyInsider Ownership
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
1.30%
Icon Plc stock logo
ICLR
Icon
44.00%
Incyte Corporation stock logo
INCY
Incyte
17.80%
IQVIA Holdings Inc. stock logo
IQV
IQVIA
1.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
20,10049.12 million48.48 millionOptionable
Icon Plc stock logo
ICLR
Icon
41,90080.76 million45.22 millionOptionable
Incyte Corporation stock logo
INCY
Incyte
2,617193.57 million159.12 millionOptionable
IQVIA Holdings Inc. stock logo
IQV
IQVIA
88,000173.00 million170.23 millionOptionable

Recent News About These Companies

IQV - IQVIA Holdings Inc Trailing Returns | Morningstar
Lupin launches generic chronic constipation treatment drug in US
Lupin rolls out constipation drug Prucalopride in US after USFDA nod
The future of healthcare advertising is wide ‘open’
Biotech Stocks Worth Watching - June 23rd

New MarketBeat Followers Over Time

Media Sentiment Over Time

Charles River Laboratories International stock logo

Charles River Laboratories International NYSE:CRL

$151.75 +1.54 (+1.02%)
Closing price 06/26/2025 03:59 PM Eastern
Extended Trading
$151.54 -0.20 (-0.13%)
As of 08:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Icon stock logo

Icon NASDAQ:ICLR

$146.75 +0.84 (+0.58%)
Closing price 06/26/2025 04:00 PM Eastern
Extended Trading
$146.73 -0.02 (-0.01%)
As of 08:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.

Incyte stock logo

Incyte NASDAQ:INCY

$70.81 +3.26 (+4.83%)
Closing price 06/26/2025 04:00 PM Eastern
Extended Trading
$71.11 +0.30 (+0.42%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

IQVIA stock logo

IQVIA NYSE:IQV

$158.00 -0.71 (-0.45%)
Closing price 06/26/2025 03:59 PM Eastern
Extended Trading
$157.50 -0.50 (-0.32%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.